Clinical and Molecular Hepatology (Clin Mol Hepatol, CMH)

Guideline

KASL clinical practice guidelines for management of chronic hepatitis B

Clin Mol Hepatol. 2022;28(2):276-331. Published online April 1, 2022

DOI: https://doi.org/10.3350/cmh.2022.0084 Correction in: Clin Mol Hepatol 2022;28(4):940

View: 8459 Download: 511 Citations: 26

Original Article

Tenofovir alafenamide treatment may not worsen the lipid profile of chronic hepatitis B patients: A propensity score-matched analysis

Joonho Jeong, Jung Woo Shin, Seok Won Jung, Eun Ji Park, Neung Hwa Park

Clin Mol Hepatol. 2022;28(2):254-264. Published online December 28, 2021

DOI: https://doi.org/10.3350/cmh.2021.0314

View: 3815 Download: 256 Citations: 11

Editorial

Dyslipidemia in chronic hepatitis B patients on tenofovir alafenamide: Facts and puzzles

Hung-Yao Lin, Tai-Chung Tseng

Clin Mol Hepatol. 2022;28(2):181-182. Published online February 21, 2022

DOI: https://doi.org/10.3350/cmh.2022.0028

View: 2805 Download: 101 Citations: 3

Review

Cost-effectiveness of chronic hepatitis C screening and treatment

Hye Won Lee, Hankil Lee, Beom Kyung Kim, Young Chang, Jae Young Jang, Do Young Kim

Clin Mol Hepatol. 2022;28(2):164-173. Published online December 27, 2021

DOI: https://doi.org/10.3350/cmh.2021.0193

View: 3840 Download: 158 Citations: 5

Approaches to quantifying hepatitis B virus covalently closed circular DNA

Henrik Zhang, Thomas Tu

Clin Mol Hepatol. 2022;28(2):135-149. Published online October 22, 2021

DOI: https://doi.org/10.3350/cmh.2021.0283

View: 5693 Download: 341 Citations: 9

Original Article

A cost-effectiveness study of universal screening for hepatitis C virus infection in South Korea: A societal perspective

Hye-Lin Kim, Kyung-Ah Kim, Gwang Hyun Choi, Eun Sun Jang, Moran Ki, Hwa Young Choi, Sook-Hyang Jeong

Clin Mol Hepatol. 2022;28(1):91-104. Published online November 5, 2021

DOI: https://doi.org/10.3350/cmh.2021.0236

View: 8504 Download: 163 Citations: 7

Review

Toward a complete cure for chronic hepatitis B: Novel therapeutic targets for hepatitis B virus

Sun Woong Kim, Jun Sik Yoon, Minjong Lee, Yuri Cho

Clin Mol Hepatol. 2022;28(1):17-30. Published online July 20, 2021

DOI: https://doi.org/10.3350/cmh.2021.0093

View: 7790 Download: 583 Citations: 23

Snapshot

History and future of hepatitis B virus control in South Korea

Do Young Kim

Clin Mol Hepatol. 2021;27(4):620-622. Published online September 23, 2021

DOI: https://doi.org/10.3350/cmh.2021.0277 Correction in: Clin Mol Hepatol 2022;28(4):939

View: 5694 Download: 138 Citations: 4

Original Article

Sofosbuvir/velpatasvir plus ribavirin for Child-Pugh B and Child-Pugh C hepatitis C virus-related cirrhosis

Chen-Hua Liu, Chi-Yi Chen, Wei-Wen Su, Chun-Jen Liu, Ching-Chu Lo, Ke-Jhang Huang, Jyh-Jou Chen, Kuo-Chih Tseng, Chi-Yang Chang, Cheng-Yuan Peng, Yu-Lueng Shih, Chia-Sheng Huang, Wei-Yu Kao, Sheng-Shun Yang, Ming-Chang Tsai, Jo-Hsuan Wu, Po-Yueh Chen, Pei-Yuan Su, Jow-Jyh Hwang, Yu-Jen Fang, Pei-Lun Lee, Chi-Wei Tseng, Fu-Jen Lee, Hsueh-Chou Lai, Tsai-Yuan Hsieh, Chun-Chao Chang, Chung-Hsin Chang, Yi-Jie Huang, Jia-Horng Kao

Clin Mol Hepatol. 2021;27(4):575-588. Published online July 13, 2021

DOI: https://doi.org/10.3350/cmh.2021.0155

View: 7564 Download: 992 Citations: 7

Review

Three heads are better than two: Hepatitis B core-related antigen as a new predictor of hepatitis B virus-related hepatocellular carcinoma

Jer-Wei Wu, Jia-Horng Kao, Tai-Chung Tseng

Clin Mol Hepatol. 2021;27(4):524-534. Published online February 23, 2021

DOI: https://doi.org/10.3350/cmh.2021.0012

View: 11983 Download: 328 Citations: 21

Original Article

The impact of unrestricted access to direct-acting antiviral among incarcerated hepatitis C virus-infected patients

Yu Jun Wong, Prem Harichander Thurairajah, Rahul Kumar, Kwong Ming Fock, Ngai Moh Law, Sin-Yoong Chong, Fria Gloriba Manejero, Tiing-Leong Ang, Eng Kiong Teo, Jessica Tan

Clin Mol Hepatol. 2021;27(3):474-485. Published online February 19, 2021

DOI: https://doi.org/10.3350/cmh.2021.0015

View: 5230 Download: 125 Citations: 7

Editorial

Risk of hepatocellular carcinoma in untreated patients with chronic hepatitis B: Independent of HBeAg status?

Ho Soo Chun, Minjong Lee

Clin Mol Hepatol. 2021;27(3):448-450. Published online June 23, 2021

DOI: https://doi.org/10.3350/cmh.2021.0130

View: 3145 Download: 112

Review

Entecavir versus tenofovir in patients with chronic hepatitis B: Enemies or partners in the prevention of hepatocellular carcinoma

Sung Won Lee, Jonggi Choi, Seung Up Kim, Young-Suk Lim

Clin Mol Hepatol. 2021;27(3):402-412. Published online June 23, 2021

DOI: https://doi.org/10.3350/cmh.2021.0179

View: 4884 Download: 235 Citations: 27

Original Article

Continuing besifovir dipivoxil maleate versus switching from tenofovir disoproxil fumarate for treatment of chronic hepatitis B: Results of 192-week phase 3 trial

Do Seon Song, Won Kim, Sang Hoon Ahn, Hyung Joon Yim, Jae Young Jang, Young Oh Kweon, Yong Kyun Cho, Yoon Jun Kim, Gun Young Hong, Dong Joon Kim, Young Kul Jung, Joo Hyun Sohn, Jin-Woo Lee, Sung Jae Park, Byung Seok Lee, Ju Hyun Kim, Hong Soo Kim, Seung Kew Yoon, Moon Young Kim, Kwan Sik Lee, Young Suk Lim, Wan Sik Lee, Jin Mo Yang, Kyun-Hwan Kim, Kwang-Hyub Han, Soon Ho Um

Clin Mol Hepatol. 2021;27(2):346-359. Published online January 25, 2021

DOI: https://doi.org/10.3350/cmh.2020.0307

View: 4687 Download: 223 Citations: 9

Significant down-regulation of growth hormone receptor expression revealed as a new unfavorable prognostic factor in hepatitis C virus-related hepatocellular carcinoma

Ching-Chih Lin, Ta-Wei Liu, Ming-Lun Yeh, Yi-Shan Tsai, Pei-Chien Tsai, Chung-Feng Huang, Jee-Fu Huang, Wan-Long Chuang, Chia-Yen Dai, Ming-Lung Yu

Clin Mol Hepatol. 2021;27(2):313-328. Published online December 14, 2020

DOI: https://doi.org/10.3350/cmh.2020.0247

View: 9381 Download: 144 Citations: 6

Negligible risks of hepatocellular carcinoma during biomarker-defined immune-tolerant phase for patients with chronic hepatitis B

Mi Young Jeon, Beom Kyung Kim, Jae Seung Lee, Hye Won Lee, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Kwang-Hyub Han, Seung Up Kim

Clin Mol Hepatol. 2021;27(2):295-304. Published online December 3, 2020

DOI: https://doi.org/10.3350/cmh.2020.0216

View: 4374 Download: 190 Citations: 18

Editorial

Another oral antiviral treatment, but still far away from hepatitis B virus cure

Tai-Chung Tseng

Clin Mol Hepatol. 2021;27(2):281-282. Published online March 10, 2021

DOI: https://doi.org/10.3350/cmh.2021.0072

View: 2993 Download: 95 Citations: 5

Negligible risk of hepatocellular carcinoma in chronic hepatitis B patients in immune-tolerant phase: Myth or fact

Terry Cheuk-Fung Yip, Grace Lai-Hung Wong, Vincent Wai-Sun Wong

Clin Mol Hepatol. 2021;27(2):273-277. Published online February 1, 2021

DOI: https://doi.org/10.3350/cmh.2021.0019

View: 3572 Download: 120 Citations: 6

Review

Current and future strategies for the treatment of chronic hepatitis C

Omar Alshuwaykh, Paul Y. Kwo

Clin Mol Hepatol. 2021;27(2):246-256. Published online December 3, 2020

DOI: https://doi.org/10.3350/cmh.2020.0230

View: 4806 Download: 227 Citations: 12

Letter to the Editor

A dilemma that probably would never resolve

Ravi Thanage, Shubham Jain, Sanjay Chandnani, Pravin Rathi

Clin Mol Hepatol. 2021;27(1):219-220. Published online December 3, 2020

DOI: https://doi.org/10.3350/cmh.2020.0274

View: 2719 Download: 68

Original Article

Persistence of intrahepatic hepatitis B virus DNA integration in patients developing hepatocellular carcinoma after hepatitis B surface antigen seroclearance

Jeong Won Jang, Jin Seoub Kim, Hye Seon Kim, Kwon Yong Tak, Heechul Nam, Pil Soo Sung, Si Hyun Bae, Jong Young Choi, Seung Kew Yoon, Lewis R. Roberts

Clin Mol Hepatol. 2021;27(1):207-218. Published online December 3, 2020

DOI: https://doi.org/10.3350/cmh.2020.0115

View: 5129 Download: 230 Citations: 21

Comedications and potential drug-drug interactions with direct-acting antivirals in hepatitis C patients on hemodialysis

Po-Yao Hsu, Yu-Ju Wei, Jia-Jung Lee, Sheng-Wen Niu, Jiun-Chi Huang, Cheng-Ting Hsu, Tyng-Yuan Jang, Ming-Lun Yeh, Ching-I Huang, Po-Cheng Liang, Yi-Hung Lin, Ming-Yen Hsieh, Meng-Hsuan Hsieh, Szu-Chia Chen, Chia-Yen Dai, Zu-Yau Lin, Shinn-Cherng Chen, Jee-Fu Huang, Jer-Ming Chang, Shang-Jyh Hwang, Wan-Long Chuang, Chung-Feng Huang, Yi-Wen Chiu, Ming-Lung Yu

Clin Mol Hepatol. 2021;27(1):186-196. Published online December 3, 2020

DOI: https://doi.org/10.3350/cmh.2020.0180

View: 5329 Download: 199 Citations: 8

Scaling up the in-hospital hepatitis C virus care cascade in Taiwan

Chung-Feng Huang, Pey-Fang Wu, Ming-Lun Yeh, Ching-I Huang, Po-Cheng Liang, Cheng-Ting Hsu, Po-Yao Hsu, Hung-Yin Liu, Ying-Chou Huang, Zu-Yau Lin, Shinn-Cherng Chen, Jee-Fu Huang, Chia-Yen Dai, Wan-Long Chuang, Ming-Lung Yu

Clin Mol Hepatol. 2021;27(1):136-143. Published online December 3, 2020

DOI: https://doi.org/10.3350/cmh.2020.0150

View: 4807 Download: 167 Citations: 24

Efficacy and safety of ledipasvir/sofosbuvir in 5,028 Mongolian patients infected with genotype 1 hepatitis C virus: A multicenter study

Oidov Baatarkhuu, Jae Seung Lee, Jazag Amarsanaa, Do Young Kim, Sang Hoon Ahn, Nyamsuren Naranzul, Damba Enkhtuya, Nagir Choijamts, Purev Batbayar, Radnaa Otgonbayar, Bat-Ulzii Saruul, Chuluunbaatar Gantuul, Baljinnyam Gegeebadrakh, Narangerel Tuvshinbayar, Dorjgotov Badamsuren, Galsan Ulzmaa, Jamiyandorj Otgonbold, Kwang-Hyub Han

Clin Mol Hepatol. 2021;27(1):125-135. Published online November 27, 2020

DOI: https://doi.org/10.3350/cmh.2020.0023

View: 4409 Download: 139 Citations: 2

Editorial

Old hepatitis B virus never dies: It just hides itself within the host genome

Jeong-Hoon Lee

Clin Mol Hepatol. 2021;27(1):107-109. Published online December 23, 2020

DOI: https://doi.org/10.3350/cmh.2020.0324

View: 3018 Download: 108 Citations: 3

Outcomes of Hepatitis C Virus Treatment with Ledipasvir/Sofosbuvir in Mongolian Population: Successes and Challenges Facing Scale-up of Care

Seong Hee Kang, Moon Young Kim

Clin Mol Hepatol. 2021;27(1):100-102. Published online December 3, 2020

DOI: https://doi.org/10.3350/cmh.2020.0312

View: 3726 Download: 69 Citations: 4

Elimination of hepatitis C: What would be the practical approach?

Hyung Joon Yim

Clin Mol Hepatol. 2021;27(1):97-99. Published online December 3, 2020

DOI: https://doi.org/10.3350/cmh.2020.0304

View: 4170 Download: 110 Citations: 2

Drug-drug interactions with direct-acting antivirals — less is more

Grace Lai-Hung Wong

Clin Mol Hepatol. 2021;27(1):81-82. Published online December 3, 2020

DOI: https://doi.org/10.3350/cmh.2020.0278

View: 3073 Download: 97 Citation: 1

Original Article

Use of glecaprevir/pibrentasvir in patients with chronic hepatitis C virus infection and severe renal impairment

Desmond Y. H. Yap, Kevin S. H. Liu, Yu-Chun Hsu, Grace L. H. Wong, Ming-Chang Tsai, Chien-Hung Chen, Ching-Sheng Hsu, Yee Tak Hui, Michael K. K. Li, Chen-Hua Liu, Yee-Man Kan, Ming-Lung Yu, Man-Fung Yuen

Clin Mol Hepatol. 2020;26(4):554-561. Published online August 28, 2020

DOI: https://doi.org/10.3350/cmh.2020.0058

View: 4267 Download: 163 Citations: 7

Editorial

More evidence that direct acting antiviral therapy is safe and effective in cirrhosis and chronic kidney disease including peritoneal dialysis

Paul Kwo, Deepti Dronamraju

Clin Mol Hepatol. 2020;26(4):489-491. Published online September 24, 2020

DOI: https://doi.org/10.3350/cmh.2020.0228

View: 3223 Download: 67 Citation: 1

Viewed By 5021	A decade of liver organoids: Advances in disease modeling
Viewed By 4775	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Viewed By 3925	Hepatitis B core-related antigen: A novel and promising surrogate biomarker to guide anti-hepatitis B virus therapy
Viewed By 3071	MAFLD: How is it different from NAFLD?
Viewed By 2488	Management of refractory ascites

Cited By 118	KASL clinical practice guidelines: Management of nonalcoholic fatty liver disease
Cited By 54	2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma
Cited By 52	From nonalcoholic fatty liver disease to metabolic-associated fatty liver disease: Big wave or ripple?
Cited By 46	Obesity and the risk of primary liver cancer: A systematic review and meta-analysis
Cited By 46	Lactobacillus attenuates progression of nonalcoholic fatty liver disease by lowering cholesterol and steatosis

Viral hepatitis